tbuckley/cabot-search huggingface dataset:
Metastasis-on-a-chip mimicking the progression of kidney cancer in the liver for predicting treatment efficacy
Authors: Yimin Wang, Di Wu, Guohua Wu, Jianguo Wu, Siming Lu, James Lo, Yong He, Chao Zhao, Xin Zhao, Hongbo Zhang, ShuQi Wang
Journal: Theranostics (2019)

Metastasis is one of the most important factors that lead to poor prognosis in cancer patients, and effective suppression of the growth of primary cancer cells in a metastatic site is paramount in averting cancer progression. However, there is a lack of biomimetic three-dimensional (3D) in vitro models that can closely mimic the continuous growth of metastatic cancer cells in an organ-specific extracellular microenvironment (ECM) for assessing effective therapeutic strategies. Methods: In this metastatic tumor progression model, kidney cancer cells (Caki-1) and hepatocytes (i.e., HepLL cells) were co-cultured at an increasing ratio from 1:9 to 9:1 in a decellularized liver matrix (DLM)/gelatin methacryloyl (GelMA)-based biomimetic liver microtissue in a microfluidic device. Results:Via this model, we successfully demonstrated a linear anti-cancer relationship between the concentration of anti-cancer drug 5-Fluorouracil (5-FU) and the percentage of Caki-1 cells in the co-culture system (R2 = 0.89). Furthermore, the Poly(lactide-co-glycolide) (PLGA)-poly(ethylene glycol) (PEG)-based delivery system showed superior efficacy to free 5-FU in killing Caki-1 cells. Conclusions: In this study, we present a novel 3D metastasis-on-a-chip model mimicking the progression of kidney cancer cells metastasized to the liver for predicting treatment efficacy. Taken together, our study proved that the tumor progression model based on metastasis-on-a-chip with organ-specific ECM would provide a valuable tool for rapidly assessing treatment regimens and developing new chemotherapeutic agents.
Macrophage Hypercellularity Accompanies Erythroid Hyperplasia in Sickle Cell Mice and during Recovery from Blood Loss in Wild Type Mice
Authors: Oluwabukola Gbotosho, Maria G Kapetanaki, Samit Ghosh, Frances Weidert, Grant C. Bullock, Solomon Fiifi Ofori-Acquah, Gregory J Kato
Journal: Blood (2019)
Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T and B-Cells and a Patient Derived Xenograft Model of Coexisting T and B-Cell Proliferations
Authors: Xiaoxian Zhao, Bartlomiej Przychodzen, Juraj Bodo, Lisa Durkin, Daniel Lindner, Neetha Parameswaran, Michael Clemente, Sarah L. Ondrejka, Jaroslaw P. Maciejewski, Deepa Jagadeesh, Eric D. Hsi
Journal: Blood (2019)
Facilitating Methadone Use in Hospitals and Skilled Nursing Facilities
Authors: Jarratt D. Pytell, Joshua M. Sharfstein, Yngvild Olsen
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
QOLP-14. CAREGIVER PERCEPTIONS OF END OF LIFE CARE IN PATIENTS WITH HIGH GRADE GLIOMA
Authors: John Fortunato, Lonni Schultz, Joel Phillips, Tobias Walbert
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Patients dying from high-grade gliomas (HGG) often suffer from a high symptom burden in the end-of-life (EoL) phase. Since patients with HGG typically do not follow up with providers in the EoL phase, information about quality of life and symptom management is sparse. Family caregivers are most informed about the patient’s symptoms and disease course. The aim of this study is to assess the quality of EoL care of HGG patients from the caregiver perspective. METHODS Caregivers participated in the Toolkit After-Death Bereaved Family Member Interview (TIME survey). This validated survey assesses EoL care by calculating “domain scores” (DS) in five different areas: 1) physical comfort and emotional support, 2) advance care planning, 3) focus on the individual, 4) attention to family, and 5) coordination of care. Caregivers also rated aspects of care using a 10 point Likert scale. RESULTS In a prospective study, 40 of 55 enrolled family caregivers completed the interview a median of 26 days after death. 68% of caregivers were female. DS indicate the quality of care. (0 = no opportunity to improve care, 1 = care was always sub-optimal). Caregivers perceived high satisfaction with information and decision-making (0.18), advance care planning (0.19), focus on the individual (0.16) and coordination of care (0.11). Attention to family (0.25) was not as well rated. Caregivers rated the overall care 8.90 ±1.36/10 on a 0–10 scale. CONCLUSIONS Caregivers reported a high overall satisfaction with EoL care provided, though attention to family could be improved. While previous research suggests the importance of good physician communication in allowing patients to die with dignity, more focus should be on the caregiver in the EoL phase to improve end of life care, caregiver burnout and bereavement.
Neutropenia in Children Treated with Deferiprone or Deferasirox: A Report of the Largest Randomized Trial of Oral Chelators in Transfusion-Dependent Pediatric Patients
Authors: Fernando Tricta, Mariagrazia Felisi, Oscar Della Pasqua, Amal El-Beshlawy, Hoda Hassab, Antonis Kattamis, Manika Kreka, Giorgio Reggiardo, Laila Metwally Sherief, Michael Spino, Bianca Tempesta, Yu-Chung Tsang, Adriana Ceci
Journal: Blood (2019)
Safety and Efficacy of Allogeneic Stem Cell Transplantation after PD-1 Blockade for Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
Authors: Anastasiya V Beynarovich, Kirill Lepik, Nataliia Mikhailova, Elena Kondakova, Yuri Zalaylov, Evgeniya Borzenkova, Elena Babenko, Elena I Darskaya, Ivan S Moiseev, Axel Zander, Boris Afanasyev
Journal: Blood (2019)
Abstract 218: Cerebral Oximetry as a Post-ROSC Predictor of Neurologic Outcome After OOHCA
Authors: Patrick Medado, Craig J Thomas, Timothy Scott, Justin Kessler, Brian O’Neil
Journal: Circulation (2012)

No reliable early predictors of neurological outcome exist for patients resuscitated from an OOHCA. Objectives: We investigated the prognostic utility of cerebral oximetry (rSO2) obtained after Return of Spontaneous Circulation (ROSC) on neurological outcome after OOHCA. Methods: This IRB approved, observational trial collected data on a convenience sample of patients presenting to an academic, urban Emergency Department with OOHCA. Cerebral Oximetry uses near infrared spectroscopy to measure oxygen in the brain independent of pulse using adhesive rSO2sensors that were placed on patient’s forehead upon ED arrival and data recorded for at least 4 hours post ROSC. We followed Utstein criteria for demographics and data recording. Blinded investigators abstracted CPC scores for all patients. Outcome measure defined as good CPC (≤ 2) at hospital discharge. We analyzed data with descriptive statistics and logistic regression. Results: We analyzed 32 patients: 69% were male, mean age 62.5 years (52 to 75), 30 (93.8%) witnessed and 23 (71.9%) had bystander CPR. Initial rhythm was VF/VT 19%, PEA 40%, Asystole 34% and 2 unknown. There were 7 (22%) with good CPC at hospital discharge. Univariate analysis showed only the average rSO2 during first 4-hours post ROSC predictive of good outcome (p&lt;0.003). Initial Mean Arterial Pressure (MAP) was a good prognosticator (p&lt;0.087). Logistic regression revealed only average rSO2 4-hours post ROSC as indicative of good outcome (p&lt;0.086). Conclusion: The average cerebral oximetry in the first 4 hours post ROSC was an excellent predictor of good neurological outcome at hospital discharge. This study is limited by small sample size and observational nature.
Genome-Wide Association Studies
Authors: Xiuqing Guo, Jerome I. Rotter
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Doubts about the adverse effects of air pollution on asthma?
Authors: Isabella Annesi-Maesano, Francesco Forastiere
Journal: European Respiratory Journal (2019)

When can a relationship between an exposure and a disease be considered "causal"? Typically, several steps need to be followed to respond to the question, such as identifying, reviewing, evaluating and integrating the scientific evidence for an overall evaluation that includes a thoughtful check of the Bradford Hill criteria [1], as illustrated in the International Agency for Research on Cancer preamble [2] or in the Environmental Protection Agency procedures [3, 4]. Efforts to reduce air pollution exposure, especially from traffic emissions, could help prevent a substantial portion of new cases of asthma <http://bit.ly/339gGdq>
HOUT-24. CHALLENGES AND SUCCESSES IN THE GLOBAL REIMBURSEMENT OF A BREAKTHROUGH MEDICAL TECHNOLOGY FOR TREATMENT OF GLIOBLASTOMA MULTIFORME
Authors: Justin Kelly, Christina Proescholdt
Journal: Neuro-Oncology (2019)

Abstract OBJECTIVE To highlight the challenges and differences regarding the reimbursement of breakthrough medical device technologies, by example of a novel cancer treatment using Tumor Treating Fields (TTFields). BACKGROUND TTFields is a breakthrough cancer treatment modality. The treatment is delivered through a medical device with the brand name Optune. Its efficacy was first established in glioblastoma multiforme. Reimbursement challenges for medical devices vary by. Common issues for novel device technologies like Optune however, are the difficulties to classify the treatment in the respective country’s health care system with the ability to develop a value-based reimbursement pathway. MATERIALS/METHODS We reviewed reimbursement decisions of payers for Optune from a total of 6 countries. We assessed their classification of the device, the flexibility of their health care framework and how Optune was implemented. RESULTS All 6 countries implemented Optune in their respective health care systems. 3 countries consider Optune to be an outpatient treatment delivered by durable medical equipment, one country classifies Optune as a hospital dispensed medical device, one country classifies Optune as an extended medical service and the last country as rehab services.The differential fitting of Optune in the respective country’s health care system allows each of the countries to take a positive, value-based reimbursement decision for this breakthrough technology. Generally, the speed of payer adoption for Optune varied based on the ability to assess the clinical data, rather than the more technical aspects of how the device is delivered to patients. CONCLUSIONS Classification of a breakthrough technology like Optune in the traditional framework of health care systems is challenging and handled differently by each country. Countries with a flexible approach regarding this novel oncological treatment modality however, were able to reach positive reimbursement decisions by classifying Optune in the category most suitable in the respective country’s health care system.
Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease
Journal: BMJ (2005)

menopausal soon after hysterectomy.We were therefore unable to carry out separate analyses using menopausal status.Previous studies have looked at risk of specific cancers after hysterectomy, rather than all cancer mortality.The reduced risk of ovarian cancer after hysterectomy found in one study 19 may have been due to a screening effect, as surgery provides an opportunity to detect abnormal ovaries.Such effects would persist for as long as it takes visible premalignant abnormalities to produce symptoms of cancer. 19This bias could have occurred in our study, although it is not clear how long such a protective effect might have influenced our risk estimates of all cancer mortality.Most women in our study had a hysterectomy for non-malignant reasons.They would no longer be at risk of endometrial, cervical, or ovarian cancer if they also had bilateral oophorectomy.Cancers comprise more than a third of deaths in middle aged women, with many at gynaecological sites.The observed lower risk of death (although not statistically significant) from all causes and from cancer among young women who had a hysterectomy was therefore unsurprising.Our results ignore any non-fatal, physical, psychological, and social costs to the individual after hysterectomy.The results should therefore not be used to argue that hysterectomy be used as a public health measure to reduce women's risk of death later in life.Instead, patients should be reassured that hysterectomy will not put their lives at risk later on.
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019
Authors: Samir Gupta, Dawn Provenzale, Xavier Llor, Amy L. Halverson, William Grady, Daniel C. Chung, Sigurdis Haraldsdottir, Arnold J. Markowitz, Thomas P. Slavin Jr, Heather Hampel, Reid M. Ness, Jennifer M. Weiss, Dennis J. Ahnen, Lee-may Chen, Gregory Cooper, Dayna S. Early, Francis M. Giardiello, Michael J. Hall, Stanley R. Hamilton, Priyanka Kanth, Jason B. Klapman, Audrey J. Lazenby, Patrick M. Lynch, Robert J. Mayer, June Mikkelson, Shajan Peter, Scott E. Regenbogen, Mary A. Dwyer, Ndiya Ogba
Journal: Journal of the National Comprehensive Cancer Network (2019)

Identifying individuals with hereditary syndromes allows for improved cancer surveillance, risk reduction, and optimized management. Establishing criteria for assessment allows for the identification of individuals who are carriers of pathogenic genetic variants. The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal provide recommendations for the assessment and management of patients with high-risk colorectal cancer syndromes. These NCCN Guidelines Insights focus on criteria for the evaluation of Lynch syndrome and considerations for use of multigene testing in the assessment of hereditary colorectal cancer syndromes.
Reduced Expression of the CD94/NKG2C NK Cell Receptor in Chronic Lymphocytic Leukemia (CLL) and CLL-like Monoclonal B-Cell Lymphocytosis (MBL)
Authors: Anna Puiggros, Gonzalo Blanco, Aura Muntasell, María Rodríguez-Rivera, Lara Nonell, Eulalia Puigdecanet, Magdalena Arnal, Xavier Calvo, Eva Gimeno, Eugenia Abella, Pau Abrisqueta, Francesc Bosch, José Yélamos, Ana Ferrer, Miguel Lopez-Botet, Blanca Espinet
Journal: Blood (2019)
Abstract 12282: Low Level Tragus Stimulation Improves Macrovascular Endothelial Function in Patients With Heart Failure With Reduced Ejection Fraction: A Randomized Pilot Study
Authors: Tarun W Dasari, Fulop Gabor, Csipo Tamas, Andriy Yabluchansky, Federico Silva, Rajesh Samannan, Stavros Stavrakis, Sunny Po
Journal: Circulation (2018)

Introduction: Endothelial dysfunction is common in HFrEF and is assessed using flow mediated vasodilation (FMD) test. Direct vagal stimulation may improve nitric oxide synthesis, thereby improving ...
Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status
Authors: Fotios Loupakis, Giulia Maddalena, Ilaria Depetris, Sabina Murgioni, Francesca Bergamo, Angelo Paolo Dei Tos, Massimo Rugge, Giada Munari, Andrew Nguyen, Christopher Szeto, Vittorina Zagonel, Sara Lonardi, Matteo Fassan
Journal: Journal for ImmunoTherapy of Cancer (2019)

<h3>Background</h3> Analysis of deficiency in DNA mismatch repair (dMMR) is currently considered a standard molecular test in all patients with colorectal cancer (CRC) for its implications in screening, prognosis and prediction of benefit from immune checkpoint inhibitors. While the molecular heterogeneity of CRC has been extensively studied in recent years, specific data on dMMR status are lacking, and its clinical consequences are unknown. <h3>Case presentation</h3> We report the case of a metastatic CRC (mCRC) patient with immunohistochemical and molecular heterogeneity in dMMR/microsatellite instability status in the primary tumour. The patient was treated with nivolumab plus ipilimumab and achieved a deep and lasting response with clear clinical benefit. Whole-exome sequencing and RNA-seq data are reported to support the evidence for molecular heterogeneity. Re-biopsy at the time of progression ruled out the selection of MMR proficient clones as an escape mechanism. A large single-institution retrospective dataset was interrogated to further explore the real incidence of heterogeneity in its different presentations. <h3>Conclusions</h3> The present case supports the efficacy of immune checkpoint inhibition in mCRC with heterogeneity in MMR/microsatellite instability status. Clinical issues that may arise in these rare patients are discussed in detail.
Mutational and Clonal Dynamics in Patient-Derived Xenografts of Acute Myeloid Leukemia
Authors: Carl Sandén, Karim Saba, Christina Orsmark-Pietras, Henrik Lilljebjörn, Carl Högberg, Marianne Rissler, Vladimir Lazarevic, Gunnar Juliusson, Helena Ågerstam, Thoas Fioretos
Journal: Blood (2016)
Disparities and Their Impact on the Adoption of Health Information Technology (HIT) in Minority Cancer Patients and Caregivers
Authors: Sikander Ailawadhi, Meghna Ailawadhi, Srilekha Bodepudi, Mays F Abdulazeez, Zan Tahir Shareef, Ashna Grover, Maria J Fernandez, Winston Tan, Victoria R. Alegria, Taimur Sher, Vivek Roy, Rami Manochakian, Aneel Paulus, Asher A. Chanan-Khan
Journal: Blood (2019)
Daratumumab-Mediated Lymphocyte Kinetics Predict Adverse Events and Survival Outcomes in Patients with Multiple Myeloma
Authors: Francesca Cottini, Nita Williams, Naresh Bumma, Abdullah Mohammad Khan, Maria Chaudhry, Srinivas Devarakonda, Yvonne A. Efebera, Don M. Benson, Ashley E. Rosko
Journal: Blood (2019)
Nicotinamide (NAM) Modulates Transcriptional Signature of Ex Vivo Cultured UCB CD34+ Cells (Omidubicel) and Preserves Their Stemness and Engraftment Potential
Authors: Tracey Lodie, Julian Adams, Dima Yackoubov, Yair Steinhardt, Dorit Ashengrau, Adi Bitansky, Alina Maliutina, Sherry Cohen, Boaz Buhenvald, Moshe Shahor, Nathan Dinowitz, Vered Caspi, Amnon Peled, Tony Peled
Journal: Blood (2019)
Microenvironmental Triggers Induce a Chemoresistant, Differentiated Subset of S100A8/A9high AML Cells Via the Jak/STAT3 Signaling Axis
Authors: Martin Boettcher, Konstantinos Panagiotidis, Kristin Mentz, Simon Voelkl, Heiko Bruns, Robert Slany, Andreas Mackensen, Dimitrios Mougiakakos
Journal: Blood (2019)
Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response
Authors: Florence Baettig, Tatjana Vlajnic, Marcus Vetter, Katharina Glatz, Jürgen Hench, Stephan Frank, Michel Bihl, Roberto Lopez, Michael Dobbie, Viola Heinzelmann-Schwarz, Céline Montavon
Journal: Journal for ImmunoTherapy of Cancer (2019)

<h3>Background</h3> Treatment options for advanced cervical cancer are limited and patients experiencing recurrence after first-line cisplatin-based chemotherapy and bevacizumab have a poor prognosis. A recent phase II study in advanced cervical cancer has demonstrated a disease control rate of 68.4% with the immune checkpoint inhibitor nivolumab. By blocking immune checkpoints, immunotherapy puts the immune system into a state of hyper-activation that can cause immune-related adverse events. We present the clinical, pathological and molecular data of a patient with metastatic cervical cancer and progressive disease after second-line therapy. We report on the therapeutic response under third-line immunotherapy with nivolumab, the immune-related adverse events (IRAE), and their successful management. <h3>Case presentation</h3> We report the case of a 62-year-old woman who was diagnosed with advanced squamous cell carcinoma of the cervix with paraaortic lymph node metastases. After an initial combined radio-chemotherapy with cisplatin, she developed local and nodal (supraclavicular) recurrence. Second-line chemotherapy with 6 cycles of carboplatin, paclitaxel, and bevacizumab resulted in a partial response for 6 months. Checkpoint inhibition with nivolumab was started due to progression, leading to persistent complete remission. Immunotherapy was well tolerated for 8 months until the patient presented with an immune-related isolated vulvitis, which was successfully managed with topical corticosteroids. <h3>Conclusions</h3> The persistent complete response after third-line treatment for relapsed chemotherapy-resistant cervical cancer presented in this case highlights the potential of immunotherapy for patients with advanced cervical cancer impressively. To our knowledge, this is the first report of an isolated immune-related vulvitis under nivolumab. This adverse event might be underdiagnosed and mistreated, however, it is of importance due to its impact on quality of life, sexual wellbeing and compliance of patients. Successful IRAE management may enable prolonged immune checkpoint inhibitor therapy. In the future, routine molecular tumour profiling is likely to aid in the stratification of cervical cancer patients for immunotherapy. Here, we provide the methylome data of a case with complete response.
The Effect of Cytogenetic Abnormalities on Organ Involvement and Survival in Patients with AL Amyloidosis
Authors: Michael Ozga, Qiuhong Zhao, Don M. Benson, Patrick Elder, Nita Williams, Naresh Bumma, Ashley E. Rosko, Maria Chaudhry, Abdullah Mohammad Khan, Srinivas Devarakonda, Rami Kahwash, Ajay Vallakati, Courtney Campbell, Samir Parikh, Salem Almaani, Jason Prosek, Elyse Redder, Yvonne A. Efebera, Nidhi Sharma
Journal: Blood (2019)